The BCG unresponsive NMIBC market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of photodynamic therapy and non-viral gene therapy, and raised awareness. LAS VEGAS , July 3, 2024 /PRNewswire/ -- DelveInsight's BCG Unresponsive NMIBC Market Insights report includes a comprehensive understanding of current treatment practices, BCG unresponsive NMIBC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the BCG Unresponsive NMIBC Market Report According to DelveInsight's analysis, the market size for BCG unresponsive NMIBCs is expected to grow significantly by 2034.
30% to 50% of cases involving non-muscle-invasive bladder cancer (NMIBC) do not respond to Bacillus Calmette-Guérin (BCG) treatment. Leading BCG unresponsive NMIBC companies such as Johnson & Johnson, enGene , and others are developing novel BCG unresponsive NMIBC drugs that can be available in the BCG unresponsive NMIBC market in the coming years. The promising BCG unresponsive NMIBC therapies in the pipeline include TAR-200 (RIS/gemcitabine plus cetrelimab), EG-70, and others.
In April 2024 , the FDA approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of .
